menu
    • menu
    [{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Acquisition","leadProduct":"Carboplatin","moa":"||PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase III","graph3":"Biotheus","amount2":0.94999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Hansoh Pharma"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PM8002","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"7","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"4","companyTruncated":"Biotheus \/ BioNTech"},{"orgOrder":0,"company":"Biotheus","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"PM8002","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase II","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotheus \/ BioNTech","highestDevelopmentStatusID":"8","companyTruncated":"Biotheus \/ BioNTech"}]

    Find Clinical Drug Pipeline Developments & Deals by Biotheus

    Menu

    Biotheus

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM8002,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : BioNTech

                            Deal Size : $950.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioNTech Completes Acquisition of Biotheus

                            Details : BioNTech strengthen its oncology portfolio and obtains full global rights to the late-stage clinical asset PM8002 (BNT327), an investigational bispecific antibody targeting PD-L1 and VEGF-A.

                            Product Name : PM8002

                            Product Type : Other Large Molecule

                            Upfront Cash : $800.0 million

                            February 03, 2025

                            Lead Product(s) : PM8002,Carboplatin,Etoposide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : BioNTech

                            Deal Size : $950.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM8002

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : BioNTech

                            Deal Size : $950.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioNTech to Acquire Biotheus to Boost Oncology Strategy

                            Details : BioNTech strengthen its oncology portfolio and obtains full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.

                            Product Name : PM8002

                            Product Type : Other Large Molecule

                            Upfront Cash : $800.0 million

                            November 13, 2024

                            Lead Product(s) : PM8002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : BioNTech

                            Deal Size : $950.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-20117

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Hansoh Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biotheus Expands Partnership with Hansoh for EGFR/cMET Bispecific Antibody Conjugates

                            Details : Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.

                            Product Name : PM1080

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            March 15, 2024

                            Lead Product(s) : HS-20117

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Hansoh Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech

                            Details : Under the terms of the agreement, Biotheus will grant BioNTech worldwide, exclusive options to a preclinical-stage bispecific antibody and a clinical-stage monoclonal antibody for cancer therapy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : BioNTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Biotheus

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PM8002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,055.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biotheus Enters into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Cand...

                            Details : BioNTech will be developing, manufacturing and commercializing PM8002, a bispecific antibody candidate being evaluated in patients with advanced solid tumors, globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater Chi...

                            Product Name : PM8002

                            Product Type : Other Large Molecule

                            Upfront Cash : $55.0 million

                            July 11, 2023

                            Lead Product(s) : PM8002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $1,055.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth